Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 13, 2025Clinical Cancer ResearchOpen Access

The Potential of the Gut Microbiota and Butyrate to Enhance CAR-T Cell Therapy in Non-Hodgkin Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

RVRoberto García VicenteARAlba Rodríguez-GarcíaRARaquel Ancos-Pintado

Discussion

Loading...

Member takes

Overview

Analysis shows gut microbiota and short-chain fatty acids improve CAR-T therapy response in non-Hodgkin lymphoma.

Key Points

  • This research aims to analyze the role of gut microbiota and butyrate in enhancing CAR-T cell therapy efficacy in patients with non-Hodgkin lymphoma.
  • Collected stool, serum, and clinical data from 84 NHL patients before CAR-T treatment.
  • Characterized microbiota through 16S rRNA gene sequencing and measured SCFAs via mass spectroscopy.
  • Studied in vitro cytotoxicity of CAR-T cells exposed to butyrate and assessed molecular mechanisms using flow cytometry and RNA-seq.
  • Confirmed the negative impact of antibiotics on microbiota diversity and CAR-T therapy response.
  • Identified SCFA-producing bacteria, such as Prevotella and Ruminococcus, linked to positive CAR-T responses.
  • Revealed that butyrate levels correlate positively with survival and might serve as a novel biomarker for response.
  • Stimulation of CAR-T cells with butyrate enhanced their antitumor efficacy through significant phenotypic and transcriptomic changes.

Cite This Study

Vicente et al. (2025) studied this question.

synapsesocial.com/papers/692523b2c0ce034ddc354782https://doi.org/10.1158/1078-0432.ccr-25-1676
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed/refractory diffuse large B cell lymphoma2025 · 5 citations
  2. 2Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope?2024 · 24 citations
  3. 3The Gut Microbiome Drives Endogenous T Cell Activation Following CAR-T Cell Therapy2026
  4. 4Multi-faceted influence of immunomodulatory metabolites on CAR-T cell therapy2025
  5. 5Data from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma2025